Global Age-Related Macular Degeneration (AMD) Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

• 2021, For the treatment of wet AMD, myopic choroidal neovascularization and retinal vein occlusion, Biogen Inc. and Samsung Bioepis Co., Ltd. received U.S. FDA approval for their biosimilar version of Lucentis under the brand name BYOOVIZ.
• 2021, A research partnership for the creation of a medication to treat people with dry age-related macular degeneration was established by Mosaic Biosciences and Ocular Therapeutix. This partnership improves the company's R&D portfolio and presents a significant possibility for the business to grow.

The Global Age-Related Macular Degeneration (AMD) Market has been segmented by Product Type into Eylea, Lucentis, Beovu, and others, with these products representing some of the most widely prescribed treatments for AMD. Eylea (aflibercept) and Lucentis (ranibizumab) are anti-VEGF (vascular endothelial growth factor) therapies used primarily to treat wet AMD by inhibiting abnormal blood vessel growth and leakage in the retina. Beovu (brolucizumab) is another anti-VEGF therapy that has been increasingly adopted for its ability to offer less frequent dosing intervals compared to Eylea and Lucentis, making it an attractive option for long-term treatment. Additionally, the "Others" category encompasses newer therapies or emerging products still undergoing clinical trials, expanding the treatment options available for AMD patients. The segment is highly competitive and dynamic, with constant innovation in drug formulations and delivery methods to improve patient outcomes.

The market is also segmented by Disease Type into Dry AMD and Wet AMD, which are the two primary forms of the condition. Wet AMD is characterized by the rapid growth of abnormal blood vessels under the retina, leading to fluid leakage and severe vision loss. It is typically treated with anti-VEGF injections, such as Eylea, Lucentis, and Beovu, which are designed to control and inhibit the growth of these blood vessels. On the other hand, Dry AMD, the more common form, is characterized by gradual thinning and aging of the macula, leading to progressive vision loss. Although treatments for dry AMD are more limited, there is increasing focus on therapies aimed at slowing disease progression and improving retinal health, such as supplements and investigational therapies.

The Distribution Channel segmentation of the AMD market includes Hospital Pharmacy, Specialty Pharmacy, and Online Pharmacy, each serving distinct patient needs. Hospital Pharmacies are crucial for administering injectables like Eylea, Lucentis, and Beovu, especially in hospital settings where patients are receiving regular treatments for wet AMD. These pharmacies also provide more personalized patient care and education. Specialty Pharmacies focus on managing complex, high-cost medications, offering specialized services like patient counseling, customized treatment plans, and home delivery for ongoing therapy, particularly for wet AMD patients. Lastly, Online Pharmacies provide greater convenience and accessibility, allowing patients to order medications such as over-the-counter supplements and, in some regions, prescription drugs like Eylea or Lucentis. However, the online pharmacy market requires rigorous safety protocols to ensure the authenticity and quality of medications, particularly in a critical therapeutic area like AMD treatment.

Global Age-Related Macular Degeneration (AMD) Segment Analysis

In this report, the Global Age-Related Macular Degeneration (AMD) Market has been segmented by Product Type, Disease Type, Distribution Channel, and Geography.

Global Age-Related Macular Degeneration (AMD) Market, Segmentation by Product Type

The Global Age-Related Macular Degeneration (AMD) Market has been segmented by Product Type into Eylea, Lucentis, Beovu, and Others.

The Global Age-Related Macular Degeneration (AMD) Market is segmented by Product Type into several key treatment options, each offering unique therapeutic benefits. Eylea is one of the most widely used anti-VEGF (vascular endothelial growth factor) inhibitors in AMD treatment. Known for its efficacy in reducing retinal fluid accumulation and improving vision in patients with wet AMD, Eylea has a strong market presence due to its proven track record. Lucentis, another anti-VEGF therapy, is also a significant player in the market. It works by inhibiting VEGF to reduce abnormal blood vessel growth in the retina, similar to Eylea, and is frequently prescribed for both wet AMD and diabetic macular edema. Beovu, a newer addition to the market, offers similar benefits in terms of targeting VEGF but is noted for its longer dosing interval, which has made it an attractive option for patients seeking less frequent treatments. The category of Others includes alternative drugs and potential therapies under clinical investigation, such as gene therapies, corticosteroids, and various novel biological agents targeting different pathways of AMD progression.

The segmentation by Product Type also highlights the competition among these treatments for market share. While Eylea and Lucentis dominate the market due to their established presence and clinical evidence, Beovu is gaining traction due to its innovative extended dosing interval, offering convenience to patients and physicians alike. The market is witnessing increasing adoption of Beovu, especially in patients with advanced wet AMD who require frequent intravitreal injections. Other treatments in the Others category are still undergoing clinical trials and may provide alternatives with improved efficacy or reduced side effects in the future, further driving market diversification and innovation.

The choice of Product Type often depends on patient-specific factors, including the severity of AMD, the presence of other ocular conditions, and the patient’s ability to adhere to frequent treatment schedules. Eylea and Lucentis are typically preferred in the initial stages of wet AMD due to their well-documented clinical efficacy, while Beovu has gained favor for its potential to reduce the frequency of injections. As the market continues to evolve, other products under the Others category may offer significant advances, driving further shifts in treatment paradigms for AMD. Overall, the diversity of product options ensures that patients have access to the most suitable therapies for their condition, promoting better management of AMD and potentially improving quality of life for those affected.

Global Age-Related Macular Degeneration (AMD) Market, Segmentation by Disease Type

The Global Age-Related Macular Degeneration (AMD) Market has been segmented by Disease Type into Dry AMD and Wet AMD.

The Global Age-Related Macular Degeneration (AMD) Market is segmented by Disease Type into Dry AMD and Wet AMD, each representing distinct pathophysiological conditions and requiring different treatment approaches. Dry AMD, the most common form of AMD, accounts for approximately 80-90% of all cases. It involves the gradual breakdown of the macula, leading to slow and progressive loss of central vision. Dry AMD is characterized by the accumulation of drusen (yellow deposits) beneath the retina, which gradually impair the macula’s function. Currently, there are limited treatment options for dry AMD, with management focused on lifestyle changes, nutritional supplements, and monitoring for progression to wet AMD, which has more aggressive and advanced treatments available.

In contrast, Wet AMD is a more severe and rapidly progressing form of the disease, accounting for the remaining 10-20% of cases. It is caused by the abnormal growth of blood vessels beneath the retina, which leak fluid and blood, leading to scarring and rapid central vision loss. Wet AMD is often treated with anti-VEGF (vascular endothelial growth factor) therapies, such as Eylea, Lucentis, and Beovu, which help to inhibit the growth of these abnormal blood vessels and reduce fluid accumulation in the retina. These treatments can significantly slow disease progression and, in some cases, restore lost vision. The wet form of AMD, though less common, is responsible for the majority of AMD-related blindness, making it a key focus of research and treatment in the AMD market.

The segmentation by Disease Type reflects the differing clinical challenges and treatment strategies for dry and wet AMD. While dry AMD lacks a definitive treatment, the focus remains on managing risk factors and preventing progression,

Global Age-Related Macular Degeneration (AMD) Market, Segmentation by Distribution Channel

The Global Age-Related Macular Degeneration (AMD) Market has been segmented by Distribution Channel into Hospital Pharmacy, Specialty Pharmacy, and Online Pharmacy.

The Global Age-Related Macular Degeneration (AMD) Market has been segmented by Distribution Channel into Hospital Pharmacy, Specialty Pharmacy, and Online Pharmacy, each playing a significant role in the availability and accessibility of treatments for AMD patients. Hospital Pharmacies are key in the distribution of prescription drugs, particularly for more complex treatments like anti-VEGF therapies for wet AMD. These pharmacies are often located within medical centers or hospitals where patients are directly treated and monitored by healthcare professionals, ensuring that patients receive the correct dosage and administration methods for their specific condition. Hospital pharmacies also tend to offer personalized services and consultations, which is important for managing conditions like AMD that require ongoing care.

Specialty Pharmacies focus on distributing high-cost, complex medications that require specialized handling and patient management. In the case of AMD, specialty pharmacies are critical for providing the latest treatments, such as Eylea, Lucentis, and Beovu, which are often used to treat the wet form of AMD. These pharmacies typically offer more tailored services, including patient education, reimbursement support, and home delivery services, which are important for ensuring patients comply with prescribed treatments and manage side effects. Given the frequent need for injections or regular medical consultations, specialty pharmacies are an important channel for patients with AMD who may require continuous or long-term therapies.

Lastly, the Online Pharmacy channel has been growing rapidly, providing increased access and convenience for patients, especially in remote areas or those who prefer to receive their medications directly at home. Online pharmacies often offer a wide range of products, including over-the-counter medications, nutritional supplements, and even prescriptions like those for AMD treatment. The rise of e-commerce has facilitated easier access to AMD therapies, particularly in regions where healthcare infrastructure might be limited or in cases where patients prefer not to visit a physical pharmacy. However, online pharmacies must ensure the authenticity and safety of their products, as the market for counterfeit drugs is a concern in the distribution of critical medications.

Global Age-Related Macular Degeneration (AMD) Market, Segmentation by Geography

In this report, the Global Age-Related Macular Degeneration (AMD) Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Age-Related Macular Degeneration (AMD) Market Share (%), by Geographical Region, 2024

In the competitive landscape of the global Age-Related Macular Degeneration (AMD) market, several key players hold significant market shares. Pharmaceutical companies focusing on developing and commercializing AMD therapies dominate this space. Among them, companies like Novartis, Roche, and Regeneron Pharmaceuticals have established strong footholds with their respective AMD treatment portfolios. Novartis, for instance, markets Lucentis (ranibizumab), a widely used anti-VEGF therapy for AMD, contributing to its substantial market share. Roche's involvement in the AMD market is notable through its partnership with Genentech, which markets Lucentis in the United States. Additionally, Regeneron Pharmaceuticals' Eylea (aflibercept) competes directly with Lucentis, offering patients an alternative treatment option and contributing to the company's market presence.

The AMD market is witnessing increasing competition from emerging biotechnology companies developing novel therapies and treatment modalities. Companies like Kodiak Sciences and Graybug Vision are advancing innovative approaches, such as longer-acting anti-VEGF agents and sustained-release drug delivery systems, aiming to address the limitations of current AMD treatments. As these companies progress through clinical trials and gain regulatory approvals, they pose a potential challenge to established players and have the potential to capture significant market shares.

The market dynamics are influenced by factors such as pricing strategies, reimbursement policies, and geographic expansion efforts. Collaborations and partnerships between pharmaceutical companies and academic institutions also play a crucial role in advancing research and development efforts in the AMD space. Overall, the global AMD market is characterized by fierce competition among established players and the emergence of innovative therapies, driving continuous efforts to improve treatment outcomes for patients affected by this debilitating eye condition.